Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
复制标题
DOI：
10.1200/jco.2007.11.9776
复制
发表时间：
2007-09-01
影响因子：
45.3
通讯作者：
Steger, Guenther G.
中科院分区：
文献类型：
--
作者：
Bartsch, Rupert;Wenzel, Catharina;Steger, Guenther G.
目的在人类表皮生长因子2（HER-2）阳性的晚期乳腺癌中，紫杉烷类或长春瑞滨联合曲妥珠单抗是最广泛应用的一线治疗方案。我们评估了卡培他滨加曲妥珠单抗后蒽环类药物和多西他赛或长春瑞滨失败和先前曲妥珠单抗exposure.Patients and MethodsForty连续患者的疗效和耐受性。卡培他滨给药剂量为1，250 mg/m2，每日2次，连续14天，每3周为1周期，必要时可调整剂量。曲妥珠单抗每3周一次给药。疾病进展时间（TTP）被定义为主要终点。每3个月使用国际抗癌联盟criteria.ResultsTTP的中位数为8个月，总生存期为24个月。二线治疗和二线以上治疗之间无显著差异。观察到2.5%的患者完全缓解（CR），17.5%的患者部分缓解（PR），50%的患者病情稳定持续至少6个月（SD），临床获益率（CR + PR + SD ≥ 6个月）为70%。腹泻（5%）和手足综合征（15%）是仅有的3级或4级严重程度的治疗相关不良事件。三例（7.5%）脑转移，而接受therapeutic.ConclusionCapecitabine加曲妥珠单抗似乎是一个有效和安全的选择，在大量的预处理人口。因此，在这种情况下，有必要将该方案与卡培他滨单药治疗进行直接比较。
PurposeIn human epidermal growth factor 2 (HER-2)-positive advanced breast cancer, taxanes or vinorelbine plus trastuzumab are among the most widely applied options in the first- line setting. We evaluated the efficacy and tolerability of capecitabine plus trastuzumab after anthracycline and docetaxel or vinorelbine failure and prior trastuzumab exposure.Patients and MethodsForty consecutive patients were included. Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary. Trastuzumab was administered every 3 weeks. Time to progression ( TTP) was defined as primary end point. Response was evaluated every 3 months using International Union Against Cancer criteria.ResultsTTP was a median of 8 months, and overall survival was 24 months. No significant difference was found for second-line and beyond second-line treatment. A complete response ( CR) was observed in 2.5%, partial response ( PR) in 17.5%, stable disease lasting at least 6 months ( SD) in 50%, resulting in a clinical benefit rate ( CR + PR + SD >= 6 months) of 70%. Diarrhea ( 5%) and hand-foot syndrome ( 15%) were the only treatment- related adverse events that occurred with grade 3 or 4 intensity. Three patients ( 7.5%) developed brain metastases while receiving therapy.ConclusionCapecitabine plus trastuzumab appears to be an effective and safe option in a heavily pretreated population. Therefore, a direct comparison of this regimen with capecitabine monotherapy in this setting is warranted.